NewAmsterdam Pharma Company N.V. (NAMS)
NASDAQ: NAMS · Real-Time Price · USD
17.46
-0.01 (-0.06%)
Apr 25, 2025, 4:00 PM EDT - Market closed
NAMS Revenue
In the year 2024, NewAmsterdam Pharma Company had annual revenue of $45.56M with 223.37% growth. NewAmsterdam Pharma Company had revenue of $12.77M in the quarter ending December 31, 2024, with 1,490.54% growth.
Revenue (ttm)
$45.56M
Revenue Growth
+223.37%
P/S Ratio
36.28
Revenue / Employee
$670,044
Employees
68
Market Cap
1.92B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 45.56M | 31.47M | 223.37% |
Dec 31, 2023 | 14.09M | -88.60M | -86.28% |
Dec 31, 2022 | 102.69M | - | - |
Dec 31, 2021 | - | - | - |
Dec 31, 2020 | - | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.90B |
NAMS News
- 21 days ago - NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 26 days ago - NewAmsterdam Pharma to Present at the 24th Annual Needham Virtual Healthcare Conference - GlobeNewsWire
- 2 months ago - NewAmsterdam Pharma: Significant Upside Possible In Case Of Approval Of Obicetrapib - Seeking Alpha
- 2 months ago - NewAmsterdam Pharma: A Mispriced Bet On A Cholesterol Revolution - Seeking Alpha
- 2 months ago - NewAmsterdam Pharma Reports Full Year 2024 Financial Results and Provides Corporate Update - GlobeNewsWire
- 2 months ago - NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in March - GlobeNewsWire
- 4 months ago - NewAmsterdam Pharma Announces Closing of Upsized $479.0 Million Public Offering of Ordinary Shares and Pre-Funded Warrants, Including Full Exercise of the Underwriters' Option to Purchase Additional Shares - GlobeNewsWire
- 4 months ago - NewAmsterdam Pharma Announces Pricing of Upsized $416.5 Million Public Offering of Ordinary Shares and Pre-Funded Warrants - GlobeNewsWire